Tirzepatide: What 129 Users Report
Dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound. Approved for type 2 diabetes and obesity; weekly injectable.
Also known as:
often mentioned with:
Related topics
Report
community guides:
Canada:
Canada, reports & related:
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
What is tirzepatide?
Tirzepatide is a once-weekly GIP and GLP-1 receptor agonist, sold by prescription as Mounjaro and Zepbound. People on this site also write it as tirz. Many of the confessions describe compounded or grey-market supply instead of a prescription. This site does not sell or recommend any source.
The side-effect numbers have their own page: tirzepatide side effects data report. This page is the wider picture: results, stalls, switches, and what happens after stopping.
What the trials show
In SURMOUNT-1, adults with obesity lost an average of 20.9% of body weight over 72 weeks at the highest dose, vs 3.1% with placebo. In SURMOUNT-5, the head-to-head trial, average loss was 20.2% with tirzepatide vs 13.7% with semaglutide. Most common side effects were gastrointestinal, mostly during dose increases; the Zepbound label also lists hair loss and fatigue above placebo. Last reviewed: October 2026.
Tirzepatide reports by the numbers
There are currently 129 published confessions tagged tirzepatide. Each was read and sorted by what the writer says happened. A report can sit in more than one row, and many are opinions, comparisons, or questions with no outcome. These are counts of stories, not rates.
| What the confession says | Count (mid-October read) | Examples |
|---|---|---|
| Also tagged retatrutide | 48 | #42, #392, #628 |
| Also tagged semaglutide | 10 | #43, #384, #668 |
| Gives a weight-loss figure | 21 | #384, #472, #816 |
| Weight loss stalled | 4 | #392, #517, #619 |
| Moved from tirzepatide to retatrutide | 7 | #42, #392, #394 |
| Weight or hunger came back after stopping | 3 | #200, #495, #614 |
| Sulfur burps or stomach trouble | 3 | #190, #276, #450 |
| Heart racing | 2 | #264, #290 |
| Less urge to drink or other compulsions | 3 | #104, #131, #820 |
| Another condition improved (migraine, reflux, A1C, allergies, anxiety) | 5 | #105, #113, #293, #308, #665 |
Tirzepatide results users describe
Weight is the main subject. #384 says semaglutide made overeating miserable while tirzepatide left "0 interest" in food, and credits it with most of a 57-pound loss. #472 reports 50 pounds. #816 is down 70. Others stall: #517 is stuck after 37 pounds, and #392 lost roughly ten pounds in eight months.
Some of the most specific reports are not about weight. #820 says the urge to drink went away. #293 describes an A1C falling from 8.3. #308 says fifteen years of reflux eased after a hard first week. These are the writers' accounts, not results to expect.
Stopping tirzepatide: what people report
#200 quit after a year and regained 30 of 50 pounds in four months. #614 stopped at goal weight and says the hunger came straight back. #590 is planning to come off at a healthy BMI. Anyone thinking about stopping a prescribed medicine should talk to the prescriber.
Tirzepatide vs retatrutide and semaglutide
Over half of these reports also name retatrutide, usually as the next step after a stall. Comparisons are collected at retatrutide vs tirzepatide and semaglutide vs tirzepatide. Neither page picks a winner. The ranked list of what fat-loss confessions mention is best peptides for fat loss.
This is not a dosing recommendation.
Anonymous tirzepatide reports
Community Q&A
- What do tirzepatide users report?
- In a mid-October read of the published tirzepatide confessions, 21 give a weight-loss figure, 4 describe a stall, and 3 describe weight or hunger returning after stopping. 5 describe another condition improving, such as migraines or reflux. These are self-reports, not trial results.
- What tirzepatide side effects come up?
- Sulfur burps and stomach trouble (#190, #276, #450) and a racing heart (#290, and #264 on a three-drug stack) appear here. The full phrase-matched counts are on the tirzepatide side effects data report.
- Do people regain weight after stopping tirzepatide?
- Three reports describe it: 30 of 50 pounds back in four months (#200), hunger returning immediately (#614), and regaining weight after tapering off two GLP-1s (#495). This is not a rate.
- Why do people switch from tirzepatide to retatrutide?
- Usually a stall. 7 reports describe moving from tirzepatide to retatrutide, and several others say they prefer tirzepatide's side-effect profile or price. See the retatrutide vs tirzepatide comparison.
- Is this page a tirzepatide dosing guide?
- No. Doses mentioned in confessions are summarised on the data report with their method. This is not a dosing recommendation, and the site does not name or recommend suppliers.
- How long does it take to lose weight on tirzepatide?
- Individual results cannot be predicted. In SURMOUNT-1, average weight loss built gradually over 72 weeks, reaching about 20% at the highest dose.
- What are the main adverse events with tirzepatide?
- Nausea, diarrhea, vomiting, constipation and reduced appetite are most common. The label also warns about pancreatitis, gallbladder disease, kidney injury from dehydration and, in a boxed warning, thyroid C-cell tumours seen in rodents.
Sources
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.